Biotech News

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Caribou (CRBU)CaribouEarnings

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data

Related news

Caribou

Genome-Edited Cell Therapy Company Caribou Biosciences applies CRISPR genome editing to create allogeneic cell therapies. Its platform was designed to produce off-the-shelf CAR T candidates with controlled edits intended to improve persistence and antitumor activity. Hematologic Oncology Programs The clinical portfolio included...

Recent company news

Stock data

Close
0.31 USD
Market cap
230.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States